Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Cytokinetics, Inc.    CYTK   US23282W1009

CYTOKINETICS, INC. (CYTK)

8
SummaryChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

CYTOKINETICS : Announces Phase I and Phase IIa Clinical Trial Results for Omecamtiv Mecarbil Published in the Journal Lancet

08/19/2011 | 08:40am US/Eastern
Recommend:
0
Results from These Trials Form the Basis For Ongoing Phase IIb Activities in Collaboration with Amgen

South San Francisco, CA - August 19, 2011

omecamtiv mecarbil, a novel cardiac myosin activator, in the August 20, 2011 issue of the journal Lancet. These two manuscripts present data regarding the safety, tolerability, pharmacokinetics and pharmacodynamic effects of this investigational drug candidate from a Phase I first-time-in-humans clinical trial in healthy volunteers and a Phase IIa clinical trial in stable heart failure patients, each sponsored by Cytokinetics. Together, these publications provide evidence for the translation into humans of this unique mechanistic approach to activating cardiac muscle contractility and support the further development of omecamtiv mecarbil as a potential treatment for heart failure. Amgen Inc. holds an exclusive, worldwide (excluding Japan) license to omecamtiv mecarbil and related compounds, subject to specified development and commercialization participation rights of Cytokinetics.

Recommend :
0
React to this article
Latest news on CYTOKINETICS, INC.
1d ago CYTOKINETICS : to Host Investor Breakfast and Webcast Following Presentation of ..
2d ago CYTOKINETICS : Announces Results From BENEFIT-ALS Will Be Presented at the 66th ..
3d ago CYTOKINETICS : CYTK) Takes Off on Strong Momentum
04/09 CYTOKINETICS : Analyst Darling Cytokinetics (CYTK) Climbs on Potential Short Squ..
04/07 CYTOKINETICS : Assigned Patent
04/01 CYTOKINETICS : to Present at the 13th Annual Needham Healthcare Conference
03/28 CYTOKINETICS : Announces the Opening to Enrollment of the Expansion Phase of COS..
03/27 CYTOKINETICS : Announces Initiation of Multiple Dose Phase I Clinical Trial of C..
03/27 CYTOKINETICS : Other Events (form 8-K)
03/07 CYTOKINETICS, INC. : CYTOKINETICS INC - 10-K - Management's Discussion and Analy..
Advertisement
Chart
Duration : Period :
Cytokinetics, Inc. Technical Analysis Chart | CYTK | US23282W1009 | 4-Traders
Income Statement Evolution
Cytokinetics, Inc. : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF